Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR
Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant near-term share gains expected in second-line
Spherix Global Insights finds rising biologic adoption across specialties, with most physicians signaling intent to adopt CLE-specific pipeline therapies earlier
New report using real-world data cites care hurdles, need for multiple meds In the U.S., having sickle cell disease (SCD) continues to
New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton,
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused
After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of
Findings show strong pre-launch awareness, safety-driven TYK2 differentiation from JAK inhibitors, and opportunity for Bristol Myers Squibb to strengthen rheumatology
Strong clinical advance perceptions and anticipated displacement of other IgAN-targeted therapies position Voyxact for meaningful early momentum, according to the
